NVIDIA and MMseqs2 Revolutionize Protein Design with GPU Acceleration

Jessie A Ellis
Jun 12, 2025 13:32
NVIDIA’s collaboration with MMseqs2 enhances protein sequence alignment using GPU acceleration, promising significant advancements in AI-driven drug discovery and protein design.
In a groundbreaking development, NVIDIA has teamed up with MMseqs2 to accelerate protein sequence alignment, a crucial process in modern biology and medicine. This collaboration utilizes GPU acceleration to enhance AI-driven drug discovery, structural prediction, and protein design, according to an article by NVIDIA.
Significance of Protein Sequence Alignment
Protein sequence alignment is vital for understanding gene functions and evolutionary relationships, which can inform drug development. By comparing new proteins with known sequences, scientists can infer their structure and function, identifying promising drug targets and disease-causing mutations. However, the rapid expansion of genomic data challenges traditional alignment tools.
Advancements in Alignment Technology
Historically, tools like BLAST were pivotal in speeding up search processes in the 1990s. However, with growing data, more efficient algorithms were needed. MMseqs2, developed in the 2010s, runs over 400 times faster than its predecessors, making it indispensable in genome annotation and drug discovery. As data volumes escalate, the shift towards GPU acceleration becomes increasingly crucial.
MMseqs2-GPU: A Leap Forward
The MMseqs2-GPU leverages GPU-specific accelerations to perform multiple sequence alignments on CUDA, significantly outperforming previous methods. The GPU version employs a parallel algorithm that directly scores alignments without gaps, enhancing speed and efficiency. Key advancements include achieving up to 100 TCUPS on eight GPUs and substantial cost reductions in protein sequence searches.
Impact on AI-Driven Workflows
Faster multiple sequence alignments (MSAs) have a substantial impact on AI-driven workflows. For instance, they dominate the inference and training times for models like AlphaFold2, with MMseqs2-GPU accelerating structure prediction by 23 times compared to traditional methods. This acceleration results in significant cost savings and efficiency improvements in drug discovery processes.
Future Directions in Bioinformatics
The collaboration between NVIDIA and MMseqs2 represents a major advancement in protein science, enabling faster insights into function, evolution, and drug discovery. As AI models increasingly integrate alignment into predictive workflows, GPU acceleration continues to redefine molecular research, promising even greater breakthroughs in medicine and biotechnology.
For more detailed insights, visit the original article on NVIDIA’s website.
Image source: Shutterstock